6920 Pointe Inverness Way, Suite 140
Fort Wayne, IN, 46804
2604073977
According to Mesoblast’s press release on April 7, 2026, “This study represents an important step forward in potentially addressing the inflammatory component of DMD, a major driver of disease progression.”
A new phase 1b study by Biogen is now evaluating the drug salanersen in patients with SMA who have already received the gene therapy Zolgensma.
On December 18, 2024, the FDA approved Ryoncil (Remestemcel-L-rknd) as the first and only off-the-shelf allogeneic bone marrow-derived mesenchymal stromal cell therapy for children who are two months old to adolescents with steroid-refractory acute graft-versus-host disease (SR-aGVHD).
